Valofane
 | |
| Clinical data | |
|---|---|
| Other names | N-carbamoyl-5-methyl-2-oxo-3-prop-2-enyloxolane-3-carboxamide |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.019.871 |
| Chemical and physical data | |
| Formula | C10H14N2O4 |
| Molar mass | 226.232 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Valofane is a sedative drug structurally related to the barbiturates[1] and similar drugs such as primidone. It is metabolized once inside the body to form the barbiturate proxibarbital (proxibarbal) and is thus a prodrug.[2]
References
[edit]- ^ Traversa U, Puppini P, Jacquot C, Vertua R (1985). "Effect of an atypical barbiturate, the 2-allophanyl-2-allyl-4-valerolactone (valofan), on exploratory behaviour and brain serotonin concentrations in mice". Journal de Pharmacologie. 16 (3): 279–90. PMID 2415778.
- ^ Lambrey B, Compagnon PL, Jacquot C (1981). "Pharmacokinetics of 14C-2-allophanyl-2-allyl -gamma-valero-lactone: a prodrug of proxibarbal in rats". European Journal of Drug Metabolism and Pharmacokinetics. 6 (3): 161–9. doi:10.1007/BF03189485. PMID 6118275. S2CID 10197120.
 | This sedative-related article is a stub. You can help Wikipedia by expanding it. |